In conclusion, our novel targeted drug delivery approach correcting the defective inhibition of IL-2R second messenger pathways in Tregs from patients with autoimmune diseases represents a highly innovative and promising strategy for potentially treating a wide range of autoimmune diseases. Here, IL2RA is linked to autoimmune disease.